Shares in AcelRx Pharmaceuticals (NSDQ:ACRX) fell more than -50% this morning after the company announced that it received a complete response letter from the FDA for its Dsuvia sufentanil sublingual tablet.
The FDA told the company that it can’t approve the new drug application in its present form, saying that AcelRx needs to collect additional data for at least 50 patients to assess the safety of the painkiller’s maximum dose described in its proposed labeling.
Get the full story at our sister site, Drug Delivery Business News.
The post AcelRx shares tumble after FDA rejects Dsuvia painkiller appeared first on MassDevice.